All In Biotech

Drug Trial Radar · NCT03937882

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3)

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

700

Actual

Start

May 24, 2019

Primary completion

Nov 8, 2020

Study completion Oct 7, 2021

Sponsor

Lead sponsor
ReGenTree, LLCIndustry
Sponsor type
Industry
First posted
May 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye Syndromes
  • Dry Eye

Interventions

  • RGN-259Drug

    A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days

  • PlaceboDrug

    It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Inferior Corneal Staining Change From Pre-CAE®(Controlled Adverse Environment) to Post-CAE® at Day 15 (Visit 4) Using the Ora Calibra® ScaleTime frame: Day 15
  2. Change From Baseline in Ocular Discomfort at Day 15 (Visit 4) Pre-CAE® Using the Ora Calibra® Ocular Discomfort & 4-Symptom QuestionnaireTime frame: Day 15

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Cornea and Cataract Consultants of Arizona

    Phoenix, Arizona

  • Eye Research Foundation

    Newport Beach, California

  • Vision Institute

    Colorado Springs, Colorado

  • Dovilan Wyatt MD, LLC

    Chicago, Illinois

  • Whitson Vision

    Indianapolis, Indiana

  • Midwest Cornea Associates, LLC

    Indianapolis, Indiana

  • The Eye Care Institute

    Louisville, Kentucky

  • Andover Eye Associates

    Andover, Massachusetts

  • Andover Eye Associates

    Raynham, Massachusetts

  • Center For Sight

    Henderson, Nevada

  • Oculus Research, Inc. at the Eye Care Center

    Raleigh, North Carolina

  • Visual Eyes Optometric

    Shelby, North Carolina

  • Bergstrom Eye Research, LLC

    Fargo, North Dakota

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania

  • Andover Eye Associates

    Warwick, Rhode Island

  • Total Eye Care, P.A.

    Memphis, Tennessee

  • Texan Eye/Keystone Research

    Austin, Texas

  • Mountain View Eye Center

    Layton, Utah

  • Country Hills Eye Center

    Ogden, Utah

  • Piedmont Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.